Kinvard Bio
Biotechnology company developing a novel class of ribosome-targeting small-molecule antibiotics through a synthetic chemistry platform. The organization focuses on discovery and preclinical development of oral and intravenous antibacterial candidates with broad-spectrum activity and designed to evade common resistance mechanisms. Programs target acute and chronic, drug-resistant infections including hospital- and community-acquired pneumonias, complicated urinary tract infections, and nontuberculous mycobacterial lung disease.
Industries
Nr. of Employees
small (1-50)
Products
Preclinical antibacterial candidate programs (lead optimization)
Small-molecule antibiotic programs derived from a synthetic macrobicyclic scaffold designed for high-affinity ribosomal binding and broad-spectrum activity; programs are being advanced in lead optimization toward IND-enabling studies.
Preclinical antibacterial candidate programs (lead optimization)
Small-molecule antibiotic programs derived from a synthetic macrobicyclic scaffold designed for high-affinity ribosomal binding and broad-spectrum activity; programs are being advanced in lead optimization toward IND-enabling studies.
Services
End-to-end medicinal chemistry, biological profiling, and preclinical optimization services to advance antibiotic candidates toward IND submission.
Management of collaborations with accelerator funds and non-dilutive grant partners to support early-stage development.
End-to-end medicinal chemistry, biological profiling, and preclinical optimization services to advance antibiotic candidates toward IND submission.
Management of collaborations with accelerator funds and non-dilutive grant partners to support early-stage development.
Expertise Areas
- Antibiotic drug discovery
- Rational drug design targeting the bacterial ribosome
- Medicinal and synthetic chemistry for macrobicyclic molecules
- Preclinical lead optimization and IND preparation
Key Technologies
- Rational structure-based drug design
- Scalable synthetic chemistry for macrobicyclic small molecules
- Ribosomal binding and target engagement assays
- In vitro susceptibility testing
News & Updates
Participation at BIO International conference (Boston, MA).
Presentation on the novel ribosome-targeting antibiotic class.
Conference participation and panel engagement on AMR investment ecosystem.
Peer-reviewed article describing a ribosome-binding antibiotic concept demonstrating activity against resistant organisms.
Publication describing a synthetic antibiotic class with activity against multidrug-resistant bacteria.
Article reporting chemical synthesis and characterization of a fluorinated macrobicyclic antibiotic scaffold.
Participation at BIO International conference (Boston, MA).
Presentation on the novel ribosome-targeting antibiotic class.
Conference participation and panel engagement on AMR investment ecosystem.
Peer-reviewed article describing a ribosome-binding antibiotic concept demonstrating activity against resistant organisms.
Publication describing a synthetic antibiotic class with activity against multidrug-resistant bacteria.
Article reporting chemical synthesis and characterization of a fluorinated macrobicyclic antibiotic scaffold.